ProNAi Therapeutics, Inc. is a DNA Interference (DNAi®)-based biopharmaceutical company that is leveraging its novel and proprietary nucleic acid-based interfering technology, DNAi®, to advance a next generation of therapies for patients with cancer and other complex genetic diseases.

ProNAi is actively seeking partners and licensing opportunities for further development of its promising DNAi® pipeline, on the strength of very compelling preclinical results to date.